2. Academic Validation
  3. The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model

The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model

  • Mov Disord. 2014 Jul;29(8):1074-9. doi: 10.1002/mds.25920.
Erwan Bezard 1,  Elsa Y Pioli,  Qin Li,  Françoise Girard,  Vincent Mutel,  Charlotte Keywood,  Francois Tison,  Olivier Rascol,  Sonia M Poli
Affiliations

Affiliation

  • 1 Motac neuroscience, Manchester, UK; Université de Bordeaux, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; CNRS, Institut des Maladies Neurodégénératives, UMR 5293, Bordeaux, France; Service de Neurologie, CHU de Bordeaux, Pessac, France; Institute of Laboratory Animal Sciences, China Academy of Medical Sciences, Beijing, China.
PMID: 24865335 DOI: 10.1002/mds.25920
Abstract

Background: Blocking metabotropic glutamate receptor type 5 (mGluR5) has been proposed as a target for levodopa-induced dyskinesias (LID) in Parkinson's disease (PD). We assessed the effect on LID of dipraglurant, a potent selective mGluR5 receptor negative allosteric modulator in the gold-standard LID macaque model.

Methods: Dipraglurant (3, 10, and 30 mg/kg, by mouth) was tested in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) macaque model of LID in a four-way crossover, single-dose, controlled study (n = 8).

Results: Dipraglurant inhibited dyskinesias in the LID macaque model, with best effect reached at 30 mg/kg dose with no alteration of levodopa efficacy.

Conclusion: Acute challenges of dipraglurant were efficacious on choreic and dystonic LID in the MPTP-macaque model. Dipraglurant pharmacokinetic variables were similar to those of levodopa, suggesting that both drugs can be co-administered simultaneously in further studies.

Keywords

MPTP; chorea; dystonia; macaque; on-time.

Figures
Products